Clinical trials: Stage III
Other Skin
Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer
This phase I/II trial studies the side effects of gene-modified immune cells (FH-MCVA2TCR) and to see how well they work in treating patients with Merkel cell cancer that has spread to other parts of the body (metastatic) or that…
- Trial name
- NCT03747484
- Testing
- Autologous MCPyV-specific HLA-A02-restricted TCR-transduced CD4+ and CD8+ T-cells FH-MCVA2TCR, Avelumab, Pembrolizumab
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Fred Hutchinson Cancer Center
Oropharyngeal Cancer
CompARE: Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer (OPC)
CompARE is a multicentre, phase III open-label randomised controlled trial using an adaptive, Multi-Arm, Multi-Stage (MAMS) design.
- Trial name
- CompARE (NCT04116047)
- Testing
- Cisplatin, Durvalumab, Radiotherapy
- Where
- 38 sites in Ireland, United Kingdom
- Volunteers
- 785 people
- Sponsor
- University of Birmingham
Non-myeloid Malignancies, Chemotherapy Induced Anaemia
A Study of Intravenous Iron Isomaltoside 1000 (Monofer®) as Mono Therapy (Without Erythropoiesis Stimulating Agents) in Comparison With Oral Iron Sulfate in Subjects With Non-myeloid Malignancies Associated With Chemotherapy Induced Anaemia (CIA)
The purpose of this study is to compare the efficacy and safety of intravenous iron therapy with oral iron therapy in patients with cancer and chemotherapy induced anaemia.
- Trial name
- NCT01145638
- Testing
- iron isomaltoside 1000, iron sulphate
- Where
- India
- Volunteers
- 350 people
- Sponsor
- Pharmacosmos A/S
Refractory Multiple Myeloma, Stage II Multiple Myeloma
Melphalan and Amifostine Followed By One or Two Autologous or Syngeneic Stem Cell Transplants and Maintenance Therapy in Treating Patients With Stage II-III Multiple Myeloma
RATIONALE: Giving chemotherapy drugs, such as melphalan, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Refractory Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
- Trial name
- NCT00217438
- Testing
- melphalan, amifostine trihydrate, peripheral blood stem cell transplantation
- Where
- 4 sites in United States
- Volunteers
- 130 people
- Sponsor
- Fred Hutchinson Cancer Center
Diphtheria, Tetanus
Immunogenicity, Safety and Tolerability of a Fully Liquid Pentavalent (DTwP-Hib-Hep B) Vaccine in Infants 6-8 Weeks of Age
This study will evaluate immunogenicity, safety and tolerability of fully liquid pentavalent vaccine (DTwP-Hib-HepB Vaccine) in infants 6-8 weeks of age.
- Conditions
- Diphtheria, Tetanus, Pertussis, Hepatitis B
- Trial name
- NCT01470287
- Testing
- DTwP-HepB-Hib Vaccine
- Where
- 3 sites in India
- Volunteers
- 175 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Breast Cancer
A Study of LY3484356 in Women With Breast Cancer Before Having Surgery
The purpose for this study is to see if the study drug, LY3484356, is safe and to determine what effects it has on breast cancer in participants with Estrogen Receptor Positive (ER+), HER2 Negative (HER2-) early stage (stage…
- Trial name
- EMBER-2 (NCT04647487)
- Testing
- LY3484356
- Where
- 19 sites in United States, Belgium and 4 more
- Volunteers
- 87 people
- Sponsor
- Eli Lilly and Company
Acute Ischemic Stroke
Monosialoganglioside in Acute Ischemic Stroke: a Randomized, Blinded and Multicenter Confirmatory Study
A multicenter, randomized, double-blind, parallel, placebo-controlled trial design is used to evaluate the efficacy and safety of GM1 injection in the treatment of patients with acute ischemic stroke.
- Trial name
- NCT06742216
- Testing
- Monosialoganglioside
- Where
- China
- Volunteers
- 1,232 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Flu, Common Cold
A Double-blind, Randomised, Parallel Group,Comparative Study With Rose-hip Liquid and Placebo Given to Healthy Volunteers in the Winter Season Aiming to Evaluate the Occurences of Flu and Catching a Cold
The trial is an investigator-initiated, double-blind, randomized, placebo-controlled phase III study. After the patient has receiving information about the study and after given written informed consent, the patient will be…
- Trial name
- NCT01459952
- Testing
- Rose hip Liquid
- Where
- Denmark
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Hyben Vital ApS
Melanoma (Skin)
Interferon Alfa Following Surgery in Treating Patients With Stage III Melanoma
RATIONALE: Interferon alfa may interfere with the growth of the cancer cells. It is not yet known if this treatment is more effective than observation following surgery for stage III melanoma.
- Trial name
- NCT00006249
- Testing
- pegylated interferon alfa, adjuvant therapy
- Where
- 104 sites in Australia, Belgium and 16 more
- Volunteers
- 1,258 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Leukemia, Lung Cancer
Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma
RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill cancer cells. Biological therapies, such as GM-CSF, may stimulate the immune system in different ways and stop cancer cells from…
- Conditions
- Leukemia, Lung Cancer, Malignant Mesothelioma, Myelodysplastic Syndromes
- Trial name
- NCT00398138
- Testing
- WT-1 analog peptide vaccine, incomplete Freund's adjuvant, sargramostim
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Uterine Sarcoma
IRCI Gynae Sarcomas, High Grade Uterine Sarcoma
This study aims to investigate a drug called Cabozantinib which belongs to a family of drugs that have effects on tumour growth, blood supply, invasion and spread.
- Trial name
- NCT01979393
- Testing
- Cabozantinib
- Where
- 15 sites in France, Italy and 3 more
- Volunteers
- 58 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Haemophilus Influenzae Type b (Hib) Infection
Study in Infants (6-12 Months) Comparing Two Doses of a Monovalent Glycoprotein-Conjugated (Diptheria Toxin -CRM197) Vaccine Versus a Tetanus Toxoid-Conjugated Vaccine Available for the Prevention of Haemophilus Influenzae Type b Infections in China
This study will evaluate the safety and efficacy of two doses of two commercially available vaccines used to prevent Haemophilus influenzae type b infections in children 6-12 months of age.
- Trial name
- NCT01044316
- Testing
- Haemophilus influenzae type b (Hib) vaccine
- Where
- China
- Volunteers
- 670 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Chronic Myeloid Leukemia in Remission
ENDURE - Efficacy and Safety of AOP2014 With CML Patients in Remission
A randomized, open-label assessor blinded, multi-center, controlled phase III Trial to evaluate the efficacy of AOP2014 administered bi-weekly subcutaneously (s.c.) in preventing molecular relapse (loss of MMR) in CML patients…
- Trial name
- ENDURE-CML-IX (NCT03117816)
- Testing
- AOP2014 / Pegylated-Proline-interferon alpha-2b, Surveillance
- Where
- 26 sites in France, Germany
- Volunteers
- 214 people
- Sponsor
- Philipps University Marburg
Refractory Multiple Myeloma, Stage I Multiple Myeloma
Randomized Trial of Cryotherapy Duration Prior to High Dose Melphalan in Myeloma Patients
The purpose of this study is to compare the effect of short-term (2 hours/120 minutes) and long-term (6 hours/360 minutes) schedules of crushed ice therapy (cryotherapy).
- Conditions
- Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
- Trial name
- NCT01653106
- Testing
- cryotherapy, questionnaire administration, pharmacological study
- Where
- United States
- Volunteers
- 148 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Ulcer
PRP ULCERAS: Clinical Trial Phase III
INTRODUCTION: Vascular ulcers are an important pathology in the daily medical practice in all the assistance levels, and they have big repercussion referring to individual, social and labour levels, supposing a big consumption of…
- Trial name
- PRPULCERAS (NCT02213952)
- Testing
- Platelet-Rich Plasma, Usual treatment
- Where
- 2 sites in Spain
- Sponsor
- Basque Health Service
Dyslipidemia, Hypertension
To Evaluate the Efficacy and Safety in Patients With Dyslipidemia and Hypertension
A Multi-center, Randomized, Double-blind, Parallel, phase III Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of JW0101+C2101 in Patients with Dyslipidemia and Hypertension.
- Trial name
- NCT05331014
- Testing
- LivaloVA, LivaloV, VA
- Where
- South Korea
- Volunteers
- 155 people
- Sponsor
- JW Pharmaceutical
Breast Cancer, Cognitive/Functional Effects
Study of Symptoms Caused by Cancer and Cancer Therapy in Patients With Invasive Breast, Lung, Prostate, or Colorectal Cancer
RATIONALE: Questionnaires that assess symptoms caused by cancer and cancer therapy may help improve the ability to plan treatment for patients with invasive cancer to help them live longer and more comfortably.
- Conditions
- Breast Cancer, Cognitive/Functional Effects, Colorectal Cancer, Lung Cancer
- Trial name
- NCT00303914
- Testing
- assessment of therapy complications, cognitive assessment, psychosocial assessment and care
- Where
- 32 sites in United States
- Volunteers
- 2,310 people
- Sponsor
- Eastern Cooperative Oncology Group
Influenza A
A Study of ZSP1273 Tablets in Patients With Acute Uncomplicated Influenza A
This is a multi-center, randomized, double-blind, placebo-controlled, and active controlled clinical trial to assess the efficacy and safety of ZSP1273 tablets in the treatment of Acute Uncomplicated influenza A.
- Trial name
- NCT04683406
- Testing
- ZSP1273 600 mg, Oseltamivir(oral)
- Where
- 76 sites in China
- Volunteers
- 750 people
- Sponsor
- Guangdong Raynovent Biotech Co., Ltd
Congestive Heart Failure
Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischemic NYHA Class III Heart Failure
This is a Phase 2 adaptive, double-blinded, placebo-controlled, randomized, multi-center trial study to evaluate the safety and efficacy of a single dose of AB-1002, administered via antegrade intracoronary artery infusion, in…
- Trial name
- GenePHIT (NCT05598333)
- Testing
- AB-1002
- Where
- 96 sites in United States, Austria and 10 more
- Volunteers
- 150 people
- Sponsor
- AskBio Inc
Breast Cancer
A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab
To verify that combination therapy with trastuzumab + pertuzumab + eribulin brings similar PFS and better QOL compared to trastuzumab + pertuzumab + taxane in advanced/recurrent HER2-positive breast cancer patients who have no…
- Trial name
- NCT03264547
- Testing
- Pertuzumab, Trastuzumab, Docetaxel
- Where
- 2 sites in Japan
- Volunteers
- 446 people
- Sponsor
- Japan Breast Cancer Research Group
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.